Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
Texto Completo: | https://www.arca.fiocruz.br/handle/icict/34394 |
Resumo: | 2020-07-24 |
id |
CRUZ_2b64caa31d1ed88a3155eab11cce568e |
---|---|
oai_identifier_str |
oai:www.arca.fiocruz.br:icict/34394 |
network_acronym_str |
CRUZ |
network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
repository_id_str |
2135 |
spelling |
Celum, ConnieHong, TingCent, AnneDonnell, DeborahMorrow, RhodaBaeten, Jared M.Firnhaber, CynthiaGrinsztejn, BeatrizHosseinipour, Mina C.Lalloo, UmeshNyirenda, MulindaRiviere, CynthiaSanchez, JorgeSantos, BrenoSupparatpinyo, KhuanchaiHakim, JamesKumarasamy, N.Campbell, Thomas B.ACTG PEARLS/A5175 Team2019-07-24T14:27:52Z2019-07-24T14:27:52Z2017CELUM, Connie et al. Herpes simplex virus type 2 acquisition among HIV-1- infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTGA5175 PEARLS Study. Journal of Infectious Diseases, v. 215, p. 907-910, 2017.1413-8670https://www.arca.fiocruz.br/handle/icict/3439410.1093/infdis/jix0291678-4391engElsevierHerpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS studyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article2020-07-24University of Washington. Department of Global Health. Seattle, WA, USA / University of Washington. Department of Medicine. Seattle, WA, USA / University of Washington. Department of Epidemiology. Seattle, WA, USA.University of Washington. Department of Global Health. Seattle, WA, USAUniversity of Washington. Laboratory Medicine. Seattle, WA, USA.University of Washington. Department of Global Health. Seattle, WA, USA / Fred Hutchinson Cancer Research Center. Seattle, WA, USA.University of Washington. Laboratory Medicine. Seattle, WA, USA / Fred Hutchinson Cancer Research Center. Seattle, WA, USA.University of Washington. Department of Global Health. Seattle, WA, USA / University of Washington. Department of Medicine. Seattle, WA, USA / University of Washington. Department of Epidemiology. Seattle, WA, USA.University of the Witwatersrand. Faculty of Health Sciences. Department of Medicine. Clinical HIV Research Unit. Johannesburg, South Africa.Fundação Oswaldo Cruz. Instituto de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Kamuzu Central Hospital. Lilongwe, Malawi.Nelson R. Mandela School of Medicine. Durban, South Africa.College of Medicine. Department of Medicine. Blantyre, Malawi.Institut Nacional de laboratoire et de Recherches. Port-au-Prince, Haiti.Asociación Civil Impacta Salud y Educación, Lima, Peru.Grupo Hospitalar Conceição. Hospital Nossa Senhora da Conceição. Serviço de Infectology. Porto Alegre, RS, Brazil.Chiang Mai University. Department of Medicine. Thailand / Chiang Mai University. Research Institute for Health Sciences. ThailandUniversity of Zimbabwe. College of Health Sciences, Harare.YRG Centre for AIDS Research and Education, Chennai, India.University of Colorado. School of Medicine. Department of Medicine. Aurora, CO, USA.Objective. Tenofovir disoproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro activity against herpes simplex virus type 2 (HSV-2) and reduced HSV-2 acquisition as preexposure prophylaxis. Whether TDF-containing antiretroviral therapy (ART) reduces HSV-2 acquisition is unknown. Design. Secondary analysis of AIDS Clinical Trials Group A5175, a randomized, open-label study of 3 ART regimens among 1571 participants. Methods. HSV-2 serostatus was assessed at baseline, at study exit, and before a change in ART regimen. Results. Of 365 HSV-2–seronegative persons, 68 acquired HSV-2, with 24 receiving TDF-containing ART and 44 receiving ART without TDF (HSV-2 seroconversion incidence, 6.42 and 6.63 cases/100 person-years, respectively; hazard ratio, 0.89; 95% confidence interval, .55–1.44). Conclusions. HSV-2 acquisition was not reduced in HIVinfected, HSV-2–uninfected persons during TDF-containing ART.HIV-1HSV-2PreventionTenofovirAntiretroviral therapyAfricainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83104https://www.arca.fiocruz.br/bitstream/icict/34394/1/license.txt79178e5f2a0eb066867a274556814938MD51ORIGINALve_Celum_Connie_etal_INI_2017.pdfve_Celum_Connie_etal_INI_2017.pdfapplication/pdf332833https://www.arca.fiocruz.br/bitstream/icict/34394/2/ve_Celum_Connie_etal_INI_2017.pdffe265bfe4c98d45f96d2dc3d58207351MD52TEXTve_Celum_Connie_etal_INI_2017.pdf.txtve_Celum_Connie_etal_INI_2017.pdf.txtExtracted texttext/plain23970https://www.arca.fiocruz.br/bitstream/icict/34394/3/ve_Celum_Connie_etal_INI_2017.pdf.txtddabcbf13bf28113fd0f22f97ac521acMD53icict/343942021-03-24 16:32:34.578oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352021-03-24T19:32:34Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.pt_BR.fl_str_mv |
Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study |
title |
Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study |
spellingShingle |
Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study Celum, Connie HIV-1 HSV-2 Prevention Tenofovir Antiretroviral therapy Africa |
title_short |
Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study |
title_full |
Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study |
title_fullStr |
Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study |
title_full_unstemmed |
Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study |
title_sort |
Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study |
author |
Celum, Connie |
author_facet |
Celum, Connie Hong, Ting Cent, Anne Donnell, Deborah Morrow, Rhoda Baeten, Jared M. Firnhaber, Cynthia Grinsztejn, Beatriz Hosseinipour, Mina C. Lalloo, Umesh Nyirenda, Mulinda Riviere, Cynthia Sanchez, Jorge Santos, Breno Supparatpinyo, Khuanchai Hakim, James Kumarasamy, N. Campbell, Thomas B. ACTG PEARLS/A5175 Team |
author_role |
author |
author2 |
Hong, Ting Cent, Anne Donnell, Deborah Morrow, Rhoda Baeten, Jared M. Firnhaber, Cynthia Grinsztejn, Beatriz Hosseinipour, Mina C. Lalloo, Umesh Nyirenda, Mulinda Riviere, Cynthia Sanchez, Jorge Santos, Breno Supparatpinyo, Khuanchai Hakim, James Kumarasamy, N. Campbell, Thomas B. ACTG PEARLS/A5175 Team |
author2_role |
author author author author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Celum, Connie Hong, Ting Cent, Anne Donnell, Deborah Morrow, Rhoda Baeten, Jared M. Firnhaber, Cynthia Grinsztejn, Beatriz Hosseinipour, Mina C. Lalloo, Umesh Nyirenda, Mulinda Riviere, Cynthia Sanchez, Jorge Santos, Breno Supparatpinyo, Khuanchai Hakim, James Kumarasamy, N. Campbell, Thomas B. ACTG PEARLS/A5175 Team |
dc.subject.en.pt_BR.fl_str_mv |
HIV-1 HSV-2 Prevention Tenofovir Antiretroviral therapy Africa |
topic |
HIV-1 HSV-2 Prevention Tenofovir Antiretroviral therapy Africa |
description |
2020-07-24 |
publishDate |
2017 |
dc.date.issued.fl_str_mv |
2017 |
dc.date.accessioned.fl_str_mv |
2019-07-24T14:27:52Z |
dc.date.available.fl_str_mv |
2019-07-24T14:27:52Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
CELUM, Connie et al. Herpes simplex virus type 2 acquisition among HIV-1- infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTGA5175 PEARLS Study. Journal of Infectious Diseases, v. 215, p. 907-910, 2017. |
dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/34394 |
dc.identifier.issn.pt_BR.fl_str_mv |
1413-8670 |
dc.identifier.doi.none.fl_str_mv |
10.1093/infdis/jix029 |
dc.identifier.eissn.none.fl_str_mv |
1678-4391 |
identifier_str_mv |
CELUM, Connie et al. Herpes simplex virus type 2 acquisition among HIV-1- infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTGA5175 PEARLS Study. Journal of Infectious Diseases, v. 215, p. 907-910, 2017. 1413-8670 10.1093/infdis/jix029 1678-4391 |
url |
https://www.arca.fiocruz.br/handle/icict/34394 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
collection |
Repositório Institucional da FIOCRUZ (ARCA) |
bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/34394/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/34394/2/ve_Celum_Connie_etal_INI_2017.pdf https://www.arca.fiocruz.br/bitstream/icict/34394/3/ve_Celum_Connie_etal_INI_2017.pdf.txt |
bitstream.checksum.fl_str_mv |
79178e5f2a0eb066867a274556814938 fe265bfe4c98d45f96d2dc3d58207351 ddabcbf13bf28113fd0f22f97ac521ac |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
_version_ |
1813008878907949056 |